TSX:AEZS - Post Discussion
Post by
prophetoffactz on Jun 09, 2024 12:47pm
Avenanthramide in combination with colchicine
Yes, colchicine and avenanthramides (AVA) reduce inflammation through independent mechanisms, and combining them is likely to enhance the reduction of inflammation in treating heart disease and other inflammatory conditions. Colchicine Mechanism
Colchicine inhibits the formation of microtubules, which are essential for many cellular functions including cell division and migration. This disrupts the inflammatory response by: - Reducing the activity of the NLRP3 inflammasome, which decreases production of pro-inflammatory cytokines like IL-1β, IL-18, and IL-6.
- Preventing the migration of neutrophils and other immune cells to sites of inflammation.
Avenanthramide Mechanism
Avenanthramides inhibit the NF-κB signaling pathway, which regulates the expression of inflammatory genes. This leads to: - Decreased production of pro-inflammatory cytokines like TNF-α, IL-6, and chemokines.
- Reduced expression of cell adhesion molecules that recruit immune cells.
Since colchicine and avenanthramides act through different mechanisms to inhibit distinct aspects of the inflammatory response, their combined use could provide an enhanced anti-inflammatory effect. This synergistic approach may be beneficial in treating inflammatory conditions like heart disease, where reducing inflammation is a key therapeutic goal.
Be the first to comment on this post